Speaker illustration

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

Member of:

European Society of Cardiology

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Lipid-lowering therapy and the atheroma

Thumbnail

PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Prevention

Session: PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

Thumbnail

Low-density lipoprotein cholesterol goal attainment and treatment patterns in a cohort of >143,000 patients with atherosclerotic cardiovascular disease in Ontario, Canada

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Treatment

Session: Coronary Artery Disease (Chronic) ePosters

Thumbnail

Clinical implications for post-ACS patients

Event: ESC Congress 2018

Topic: Treatment

Session: Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

Thumbnail

Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study

Event: ESC CONGRESS 2016

Topic: Thrombosis and platelets

Session: Dual antiplatelet therapy: the long and the short of it!

Thumbnail

How might PCSK9 inhibition change this debate?

Event: ESC CONGRESS 2014

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: New frontiers in cholesterol management in high cardiovascular risk patients

Thumbnail

ESC 365 is supported by

logo Novo Nordisk